araag2/HINT huggingface dataset:
Clinical trial NCT00467012 (phase 2, status: completed)
Conditions: metastatic breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: bevacizumab, paclitaxel
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        -  At least 20 years old and obtained a written informed consent

          -  Advanced breast cancer (StageⅣ) or Inoperable metastatic breast cancer

          -  HER2 negative

          -  At least one measurable lesion based on RECIST criteria

          -  No previous chemotherapy for metastatic breast cancer
Clinical trial NCT00490061 (phase 2, status: terminated)
Conditions: head and neck cancer, carcinoma, squamous cell, head and neck cancers
ICD codes: C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11, C44.520, C44.92, C44.02, C44.321, C44.521, C44.82, C44.42, C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11
Drugs: lapatinib
SMILES: CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1
Reason stopped: 
    poor accrual.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Newly diagnosed stage III-IV HNSCC, pathologically confirmed (HNSCC from unknown
             primary sites are allowed)

          -  No evidence of distant metastasis

          -  No prior radiation therapy to the head and neck sites.

          -  Able to sign a study-specific informed consent form.

          -  Women of childbearing potential and men with partners capable of producing offspring
             must be willing to practice acceptable methods of birth control to prevent pregnancy.

          -  Left ventricular ejection fraction (LVEF) within the institutional normal range as
             measured by ECHO (If ECHO cannot be performed or if the Investigator feels that it is
             not conclusive to evaluate LVEF, then a MUGA scan should be performed).

          -  Having one of the following parameters that would preclude the use of concurrent CRT:

               -  ECOG PS > 2.

               -  Creatinine > 1.3 or calculate or measure creatinine clearance < 60 ml/min.

               -  AST or ALT > 1.5 times normal limit but < 3 times normal limit

               -  Total bilirubin > 1.5 mg/dL but < 3mg/dL

               -  History of hearing loss that would preclude cisplatin chemotherapy. These would
                  include the existing need of a hearing aid or a >= 25 decibel shift over 2
                  contiguous frequencies on a pretreatment hearing test.

               -  Pre-existing peripheral neuropathy that would preclude cisplatin chemotherapy

               -  Refuse or cannot tolerate chemotherapy

          -  Age 18 years or older

        Exclusion Criteria:

          -  Known hypersensitivity to lapatinib or any of the excipients of this product
             (quinazolines).

          -  Uncontrolled angina, arrhythmia or congestive heart failure at the time of HNSCC
             diagnosis and treatment.

          -  History of myocardial infarction < 6 months from study entry.

          -  Treatment with a non-approved or investigational drug within 30 days before Day 1 of
             study treatment.

          -  Prior treatment with EGFR or Her2/Neu directed therapies.

          -  HIV-positive patients receiving combination anti-retroviral therapy are excluded from
             the study because of possible pharmacokinetic interactions with Lapatinib.

          -  Absolute neutrophil count < 1500/uL
Clinical trial NCT00570778 (phase 2, status: completed)
Conditions: chronic obstructive pulmonary disease (copd)
ICD codes: G91.1, I42.1, N11.1, J05.0, G47.33, J44.9, N13.8
Drugs: indacaterol/glycopyrrolate, indacaterol, placebo
SMILES: C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1, CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Male or female adults aged ≥40 years, who have signed an Informed Consent Form prior
             to initiation of any study-related procedure.

          2. Patients with moderate to severe stable Chronic Obstructive Pulmonary Disease (COPD)
             according to the Global Initiative for Obstructive Lung Disease (GOLD) Guidelines
             2006.

          3. Patients who have smoking history of at least 10 pack years.

          4. Patients with a post-bronchodilator Forced Expiratory Volume in 1 second (FEV1) ≥30%
             and < 80% of the predicted normal and post-bronchodilator FEV1/Forced Vital Capacity
             (FVC) <0.70.

        Exclusion Criteria:

          1. Pregnant or nursing women, or women of child-bearing potential, regardless of whether
             or not sexually active if they are not using acceptable methods of contraception.

          2. Patients requiring long term oxygen therapy (> 15 hours a day) on a daily basis for
             chronic hypoxemia, or who have been hospitalized or visited an emergency department
             for a COPD exacerbation or as result of their airways disease in the 6 weeks prior to
             screening.

          3. Patients who have had a respiratory tract infection within 6 weeks prior to screening.

          4. Patients with concomitant pulmonary disease, pulmonary tuberculosis (unless confirmed
             by chest x-ray to be no longer active) or clinically significant bronchiectasis.

          5. Patients with any history of asthma indicated by (but not limited to) a blood
             eosinophil count > 400/mm3.

          6. Patients who, in the judgment of the investigator or the responsible Novartis
             personnel, have a clinically relevant laboratory abnormality or a clinically
             significant condition.

          7. Patients with uncontrolled Type I and Type II diabetes.

          8. History of malignancy of any organ system (including lung cancer), treated or
             untreated, within the past 5 years.

          9. Patients who are contraindicated for or who have shown an untoward reaction to inhaled
             anticholinergic agents.

         10. Patients with a history of long QT syndrome or whose QTc interval (Fridericia method)
             measured at screening is prolonged (>450 ms for males or >470 ms for females).

         11. Patients with a history of untoward reactions to sympathomimetic amines, inhaled
             medication or any component thereof, or any of the study drugs or drugs with similar
             chemical structures.

        Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT00569972 (phase 2, status: completed)
Conditions: insomnia
ICD codes: F51.01, F51.02, F51.03, F51.04, G47.00, G47.09, A81.83
Drugs: pd 0200390, pd 0200390, pd 0200390, pd 0200390, placebo
SMILES: C[C@H]1CC(CN)(CC(O)=O)C[C@@H]1C, C[C@H]1CC(CN)(CC(O)=O)C[C@@H]1C, C[C@H]1CC(CN)(CC(O)=O)C[C@@H]1C, C[C@H]1CC(CN)(CC(O)=O)C[C@@H]1C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  3 month history of primary insomnia;

          -  18 to 64 years

          -  For the last 3 months-regularly awake unrefreshed and unrestored

          -  Difficulty initiating and maintaining sleep for at least 3 nights/week for the past
             month (difficulty falling asleep, difficulty staying asleep, early awakening)

        Exclusion Criteria:

          -  Any history of an Axis 1 psychiatric diagnosis;

          -  History or presence of any breathing related sleep disorder;

          -  History or presence of any medical or neurological condition that could interfere with
             sleep

          -  Use of alcohol as a sleep aid or more than 2 standard drinks consumed per day or more
             than 14 consumed per week
Clinical trial NCT01674348 (phase 2, status: terminated)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: p2202, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    due to non-recruitment, the study is being halted. there are no major safety or tolerability
    concerns in the study conducted so far.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects who understand and are willing to give informed consent to participate in the
             trial.

          -  Adult male and female subjects between 18 years to 65 years of age with a BMI ≥ 27
             kg/m2 ≤ 40 kg/m2, inclusively.

          -  Subjects with established type 2 diabetes mellitus of at least 3 months duration at
             the time of screening.

          -  Subjects with an inadequate glycemic control defined by an HbA1c level of ≥ 7.5% and
             ≥10% at screening.

          -  Subjects who are on a stable dose of:

               -  Metformin (up to 2.55 gm/day or maximum tolerated dose of at least 1 gm/day)
                  and/or

               -  Sulfonylurea (glimepiride ≤ 4 mg/day, gliclazide ≤ 160 mg, glibenclamide or
                  glyburide ≤ 10 mg and glipizide ≤ 10 mg), for ≤ 2 months prior to the screening
                  visit.

          -  Subjects with fasting plasma glucose of ≤14.4 mmol/L (260 mg/dL) and at least 5.5
             mmol/L or 100 mg/dL.

        Exclusion Criteria:

          -  Subjects who have type 1 diabetes mellitus, maturity-onset diabetes of the young or
             any rare form of diabetes. Subjects with hyperglycemia due to secondary causes.

          -  Subjects who have had more than 4 episodes of severe hypoglycemia in the 6 months
             prior to screening.

          -  Subjects with a history of acute diabetic complications

          -  Subjects who have been treated with insulin (except for use of insulin for short term
             management of acute conditions), thiazolidinediones, dual proliferator activated
             receptors agonists, glucagon-like peptide analogues, dipeptidyl peptidase inhibitors
             or 11bHSD-1 inhibitors in any form, in the 3 months prior to screening.

          -  Subjects who are receiving systemic glucocorticoids (≥14 days)
Clinical trial NCT01022970 (phase 2, status: completed)
Conditions: eosinophilic esophagitis
ICD codes: K20.0
Drugs: qax576 placebo, qax576
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females aged 18-50 with symptomatic eosinophilic esophagitis

          -  Female subjects must be women of non child bearing potential.

          -  Elimination diet must have been tried.

          -  Treatment for at least two months prior to enrollment on a protocol pump inhibitor .

          -  Appropriate contraception must be used by males, (e.g., spermicidal gel plus condom)

          -  Must be able to communicate well with the investigator, to understand and comply with
             the requirements of the study.

          -  Understand and sign the written informed consent.

        Exclusion criteria:

          -  Have received corticosteroids within 3 months before starting the study for any
             symptoms.

          -  Any other eosinophilic disorders.

          -  History of clinical schistosomiasis, or having travelled within the preceding 6 months
             to an area with endemic schistosomiasis, including but not limited to Southeast and
             Southwest Asia, South America and Africa. Travel to these areas must not be planned
             for at least 6 months after the last dose.

          -  Donation or loss of 400 ml or more of blood within eight (8) weeks prior to initial
             dosing.

          -  History of immunodeficiency diseases, including a positive HIV (ELISA and Western
             blot) test result.

          -  History of drug or alcohol abuse within the 12 months prior to dosing, or evidence of
             such abuse as indicated by the laboratory assays conducted during the screening.

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00361244 (phase 1/phase 2, status: terminated)
Conditions: colorectal carcinoma
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: su011248, irinotecan, cetuximab
SMILES: CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=CC=CC=C4N=C13)C2=O, [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologic proof of adenocarcinoma of the colon or rectum with evidence of metastatic
             disease. The site of the primary lesion must be or have been confirmed endoscopically,
             radiologically, or surgically to be or have been in the large bowel

          -  Patients must have received one (and only one) prior chemotherapy regimen for
             metastatic disease using 5-FU/LV or Xeloda in combination with oxaliplatin and
             Avastin.

          -  > 4 weeks must have elapsed from the time of major surgery

          -  > 2 weeks must have elapsed from the time of minor surgery

          -  > 4 weeks must have elapsed from the time of major radiotherapy

          -  Normal organ and marrow function

          -  Measurable disease be RECIST criteria

          -  Older than 18 years of age

          -  ECOG performance status of 0-1

          -  Life expectancy > 12 weeks

        Exclusion Criteria:

          -  Previous treatment with irinotecan, cetuximab or SU011248

          -  Any of the following within the 12 months prior to study drug administration:
             severe/unstable angina; myocardial infarction; symptomatic congestive heart failure;
             cerebrovascular accident; or transient ischemic attack.

          -  Known brain metastases or carcinomatous meningitis

          -  Uncontrolled serious medical or psychiatric illness

          -  NCI CTCAE grade 3 or greater hemorrhage within 4 weeks of starting study treatment

          -  Uncontrolled hypertension

          -  Diagnosis of any secondary malignancies with the last 5 years, except for adequately
             treated basal cell carcinoma, squamous cell skin cancer, localized prostate cancer
             with a normal PSA within the past 3 months, in situ bladder cancer, or in situ
             cervical cancer

          -  Pregnant or breastfeeding

          -  Concurrent treatment on another clinical trial
Clinical trial NCT00723346 (phase 1/phase 2, status: completed)
Conditions: acute lymphoblastic leukemia
ICD codes: C91.01, C91.02, C91.00
Drugs: native l asparaginase
SMILES: N[C@@H](CC(O)=O)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subject between 1 and 55 year old

          -  Subject with acute lymphoblastic leukaemia or lymphoblastic lymphoma (excluded burkitt
             lymphoma) who have relapsed after first remission (medullary or SNC relapse)

          -  Or patient who still refractory to first line chemotherapy for an ALL

          -  Patient who gave written informed consent (2 parents for children)

        Exclusion Criteria:
Clinical trial NCT00141557 (phase 2, status: terminated)
Conditions: menopause
ICD codes: E28.310, E28.319
Drugs: esterified estrogens 1.25mg and methyltestosterone 2.5mg, esterified estrogens 1.25 mg
SMILES: [H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
Reason stopped: 
    lack of enrollment
  
Eligibility criteria:

        Inclusion Criteria:

        Hysterectomized, menopausal women between the ages of 30 and 65 years of age (inclusive)
        with symptoms of estrogen and/or androgen deficiency not currently controlled by estrogen
        therapy as determined by patient report and the Investigator's clinical judgement
Clinical trial NCT01294410 (phase 2, status: completed)
Conditions: colitis, ulcerative
ICD codes: K51.80, K51.813, K51.814, K51.90, K51.913, K51.914, K51.811
Drugs: placebo, placebo, anti-ip-10 antibody, anti-ip-10 antibody, anti-ip-10 antibody, anti-ip-10 antibody, anti-ip-10 antibody, anti-ip-10 antibody
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical diagnosis of moderate to severe UC confirmed by endoscopic and histologic
             evidence

          -  Mayo score ≥6 with an endoscopic subscore of ≥2

          -  Inadequate response and/or intolerance to one or more conventional therapy (i.e. oral
             aminosalicylates, immunosuppressants, corticosteroids, and/or TNF antagonist)

        Exclusion Criteria:

          -  Diagnosis of Crohn's Disease or Indeterminate Colitis

          -  Diagnosis of UC that is limited to the rectum

          -  Evidence of fulminant colitis, toxic megacolon, or bowel perforation

          -  Current need for a colostomy or ileostomy

          -  Previous total or subtotal colectomy
Clinical trial NCT00531687 (phase 2, status: terminated)
Conditions: testicular cancer
ICD codes: E29.0, E29.1, E29.8, E29.9, E89.5, N50.811, N50.812
Drugs: paclitaxel, cisplatin, gemcitabine
SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed germ cell tumor (seminoma or non-seminoma) with measurable
             metastatic disease either by radiography (at a site which has previously not been
             irradiated) or elevation of alpha fetoprotein (AFP) and/or elevation of beta-human
             chorionic gonadotropin (beta-HCG);

          -  Patient previously treated with standard BEP (3 or 4 cycles) with relapse 1 months or
             more after favorable response on previous chemotherapy (CR or PR)

          -  Male

          -  Age greater than or equal to 18 years;

          -  Performance status 0,1,2 or 3

          -  WBC > 3000 mill/l, ANC > 1500 mill/l, platelet count > 100.000 mill/l; serum bilirubin
             < 1.5 x the upper limit of normal;

          -  Adequate renal function (Glomerular Filtration Rate (GFR) >60 ml/min). GFR will be
             assessed by direct measurement (EDTA clearance or creatinine clearance)

          -  signed informed consent;

        Exclusion Criteria:

          -  Uncontrolled active severe clinical infection (CTC grade 3 or 4).

          -  Serious concomitant systemic disorders incompatible with the study (at the discretion
             of the investigator), including expected difficulty of follow-up related to mental
             disorders.

          -  Grade 2 or greater peripheral neuropathy according to the CTC, version 3.0.

          -  Second malignancy other than basal or squamous cell skin cancer.
Clinical trial NCT01181609 (phase 2, status: completed)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: bevacizumab [avastin]
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with metastatic colon or rectal cancer, progressing or relapsing after
             first-line treatment;

          -  Women of childbearing potential must use adequate contraception up to at least 6
             months after the last dose of bevacizumab.

        Exclusion Criteria:

          -  Patients with metastatic colon or rectal cancer scheduled for a first-line systemic
             treatment;

          -  Untreated brain metastases, spinal cord compression or primary brain tumours;

          -  Pregnant or lactating women;

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to study start;

          -  Treatment with any investigational drug, or participation in another investigational
             study, within 30 days prior to enrollment.
Clinical trial NCT00479505 (phase 2, status: completed)
Conditions: urinary bladder, overactive
ICD codes: N32.81
Drugs: uk-369,003, placebo
SMILES: CCOC1=NC=C(C=C1C1=NC2=C(CC)N(CCOC)N=C2C(=O)N1)S(=O)(=O)N1CCN(CC)CC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male subjects aged 18 years and above

          -  documented clinical diagnosis of overactive bladder with urinary frequency >= 8 times
             / 24 hours and number of urgency episodes > 1 episode / 24 hours.

        Exclusion Criteria:

          -  Neurological diseases known to affect bladder function.

          -  Urinary tract infection.
Clinical trial NCT01679041 (phase 2, status: terminated)
Conditions: multiple sclerosis
ICD codes: G35, C81.18
Drugs: alemtuzumab, fludarabine, cyclophosphamide
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1
Reason stopped: 
    insufficient accruals; pi leaving site
  
Eligibility criteria:

        Inclusion Criteria:

        Age between 18-60, inclusive

        Patients carry a diagnosis of multiple sclerosis, according to the McDonald's criteria for
        diagnosis (Polman et al, 2011).

        Must have a neurologist providing the primary care for the MS and be willing to be
        evaluated for the multiple sclerosis by the two neurologists who are the co-investigators
        in the protocol.

        Must be documented to be HIV negative.

        An EDSS of 3.5 - 5.5

        Patients must be able to give written consent.

        Inflammatory disease despite primary disease modifying therapy with at least 6 months of
        interferon and another disease modifying therapy, including fingolimod,glativamir,
        natalizumab, and mitoxantrone. Failure is defined as two or more clinical relapses with
        documented neurologic changes (excluding sensory changes) within the year prior to the
        study. (NOTE: Relapses must have required treatment with corticosteroids). Failure may also
        be defined as one relapse (excluding sensory changes) treated with methylprednisone and, on
        a separate occasion within the previous 12 months, evidence of active inflammation (i.e.
        gadolinium enhancement on MRI scan of the CNS).

        No previous history of allergic reaction to cyclophosphamide, G-CSF or mesna

        Patients must not be pregnant

        Failure to accept or comprehend irreversible sterility as a potential side effect of
        therapy.

        Life expectancy of more than 6 months

        No evidence of myelodysplastic syndrome on peripheral blood smear

        Not allergic to cyclophosphamide, mesna, fludarabine or alemtuzumab

        Baseline serum creatinine must be <1.5 mg/dL, left ventricular ejection fraction >55%,
        adequate pulmonary functions (oxygen saturation at room air of >90%), and AST and ALT not >
        2x upper limits of normal, and no history of previous or active malignancy, except for
        localized cutaneous basal or squamous cell carcinoma in situ of the cervix.

        Exclusion Criteria:

        Diagnosis of primary progressive MS.